Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-22

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 33

Registration Number: NCT00003309

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States
🇺🇸
Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

and more 11 locations

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma: Hodgkin
Lymphoma, Hodgkin Disease
Hodgkin Disease
Lymphoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone
Drug: Bleomycin
Drug: Etoposide
Radiation: Low-dose radiotherapy (RT)

First Posted Date: 2003-01-27

Last Posted Date: 2018-07-24

Lead Sponsor: Stanford University

Target Recruit Count: 76

Registration Number: NCT00026208

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States

Combination Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Stage IIIB Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2012-07-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 5

Registration Number: NCT00021112

Locations: 🇳🇱
Academisch Ziekenhuis Utrecht, Utrecht, Netherlands
🇧🇪
Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇳🇱
University Hospital - Rotterdam Dijkzigt, Rotterdam, Netherlands

and more 7 locations

Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed or Progressive B-Cell Diffuse Large Cell Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 427

Registration Number: NCT00052923

Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: Lymphoma Trials Office

Target Recruit Count: 30

Registration Number: NCT00032149

Locations: 🇬🇧
King's College Hospital, London, England, United Kingdom
🇬🇧
St. Georges, University of London, London, England, United Kingdom
🇬🇧
Cheltenham General Hospital, Cheltenham, England, United Kingdom

and more 1 locations

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Large Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma

Interventions: Biological: rituximab
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: prednisone
Drug: cyclophosphamide
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 106

Registration Number: NCT00049036

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: etoposide
Drug: exisulind

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 41

Registration Number: NCT00041054

Locations: 🇺🇸
Broward General Medical Center, Fort Lauderdale, Florida, United States
🇺🇸
MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 80 locations

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-03-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00040872

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: EBMT Solid Tumors Working Party

Target Recruit Count: 430

Registration Number: NCT00011921

Locations: 🇨🇭
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor

Phase 3

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 350

Registration Number: NCT00047138

Locations: 🇩🇪
Universitaetsklinikum des Saarlandes, Homburg, Germany
🇫🇷
Institut Gustave Roussy, Villejuif, France
🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy